Qualcomm Incorporated

Huawei Technologies Co., Limited

Chinese Academy of Sciences

Shanghai Jiao Tong University

Other

Nokia Solutions and Networks Oy

General Electric Company

Nokia Technologies Oy

Sony Group Corporation

Firmenich Sa

Delta Electronics (Shanghai) Co., Ltd

Electronic Arts Inc.

Telefonaktiebolaget Lm Ericsson (Publ)

Dow Global Technolgoies LLC

Merck Sharp + Dohme Corp.

Jian Li

Shuhui Chen

Haiying He

Peng Li

Changlong Xu

Liangming Wu

Hao Xu

Peng Zhang

Yu Zhang

Dengke Cai

Fei Wang

Fang Liu

Chao Wei

Jilei Hou

Yi Liu

Chen Zhang

Lei Zhang

Ruiming Zheng

Hao Wu

Xipeng Zhu

Xing Liu

Chenxi Hao

Qiaoyu Li

Yu Chen Zhou

Gary Robert Allen

Xin Wang

Wei He

Jing Jiang

Thomas J Richardson

Chen Sun

Peng Cheng

Liang Zhang

Jian Wang

Wei Luo

Min Huang

Yan Wang

Xiaoyan Bi

Yan Chen

Wei Zhang

Jinfa Zhang

Yong Liang Liu

Jing Li

Nevenka Dimitrova

Liang Jie Xu

Wei Huang

Wei Wang

Craig Alan Coburn

Yong Wang

Guoping Hu

Charles Z Ding

Jie Li

Kevin X Chen

Hualiang Jiang

Kaixian Chen

Lihong Hu

Hong Tao Liu

Zhiyong Wang

Jiang Wang

Xiaolin Li

Jia Tao Li

Chengde Wu

Yunfu Luo

Yuan Chen

Kai Zhou

Thomas Clynne

Yuankun Zhu

Fei Sun

Xiao Xun Zhang

Xiquan Zhang

Zheng Wang

Kun Xiao

Dageng Chen

Jian Ding

Jian Zhou

Bin Hu

Tao Cui

Kun Liu

Jun Yin

Hongwei Li

Feng Gao

Yi Chen

Jun Zhu

Peng Wu

Jing Wang

Yang Zhang

Shawn J Stachel

Meiyu Geng

Hui Chen

Liang Hu

Hongjiang Xu

Jing Dai

Lu Zhang

Ling Yang

Chun Sing Li

Provided are a thiazololactam compound, and the use thereof in the preparation of a drug for treating ERK-related diseases. Specially, the present invention provides a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof.

Thiazololactam compound as ERK inhibitor and use thereof

Disclosed are a kind of fused ring derivatives, and specifically disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

Fused ring derivatives and use thereof in pharmacy

Sulfonylurea ring substituted monocyclic β-lactam antibiotics, and specifically relating to a compound represented by formula (I), a pharmaceutically acceptable salt or a stereoisomer thereof, and an application thereof in the preparation of medicaments for treating diseases related to bacterial infections.

Sulfonylurea ring substituted monocyclic β-lactam antibiotics

The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Fluorovinylbenzamide compound as PD-L1 immunomodulator

Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Compound as highly selective ROS1 inhibitor and use thereof

Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive, from a base station, a configuration indicating a set of encoding parameters corresponding to a constellation shaping encoding process. The UE may calculate a number of bits of a first subset of a source bit stream, and the first subset of the source bit stream may include or encompass an input to a distribution matcher. The UE may apply, to the first subset, a distribution matcher parameter based on the set of encoding parameters. The UE may calculate a number of bits of a second subset of the source bit stream, and the second subset of the source bit stream may be concatenated with an output bit stream of the distribution matcher as an input to a channel encoder. The UE may signal the source bit stream to the base station.

Constellation shaping configuration and feedback

Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof

A request-response based paravirtualized I/O system and method relating to the fields of virtualization and cloud computing includes a request-response application, a front-end drive module and a back-end drive module. The front-end drive module and the back-end drive module interact by means of a transmit queue and a receive queue. The request-response application generates an I/O request, and the front-end drive module writes the I/O request into the transmit queue. The system has two operating modes: a notification mode and a polling mode. The system operates by default in the notification mode. When the request-response application issues a connection establishment or service request, the system switches to the polling mode. This system and method introduce an optimistic polling mechanism, combine the advantages of the notification mode and the polling mode, reduce the number of VM exits and decrease wasting of computing resources, thus improving data path performance.

Request-response based paravirtualized I/O system and method

Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit, to another UE, a set of encoded packets associated with a vehicle-to-everything (V2X) communication, wherein the set of encoded packets are generated according to a network coding scheme, transmit, to a relay device, the set of encoded packets associated with the V2X communication, and receive, from the relay device, an acknowledgment message based at least in part on transmitting, to the relay device, the set of encoded packets associated with the V2X communication. Numerous other aspects are provided.

Vehicle-to-everything communications using network coding assisted by a relay

Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyrrolotriazine compounds acting as MNK inhibitor

In one aspect of the disclosure, a method of wireless communication performed by a receiving device includes receiving, from a transmitting device, a plurality of encoded packets each including at least one respective physical (PHY) layer symbol. The method includes decoding the plurality of encoded packets based on a raptor code to generate received data. The method also includes determining a signal-to-interference-plus-noise ratio (SINR) associated with receiving the plurality of encoded packets, receiving an indication from the transmitting device, or determining a channel quality indicator (CQI) or a modulation and coding scheme (MCS) associated with receiving the plurality of encoded packets. The method further includes adaptively determining a PHY packet error rate associated with the plurality of encoded packets based on the SINR, the indication, the CQI, or the MCS. Other aspects and features are also claimed and described.

Packet encoding based on raptor codes to enable adaptive physical layer error rate determination or selection

Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

Compound for use in retinal diseases

Crystalline forms of an ATR inhibitor, preparation methods therefor, and the use thereof in the preparation of a drug for treating ATR-related diseases. In particular, crystalline forms of an ATR inhibitor represented by formula (I), physicochemical and biochemical properties of the same, preparation methods for, and uses of the same, in the preparation of a drug for treating ATR-related diseases.

Crystalline form of ATR inhibitor and use thereof

A crystal form of a pyridinylphenyl compound and a preparation method therefor. Use of the crystal form in the preparation of a medicament of treating related diseases is also comprised.

Crystal form of pyridinylphenyl compound and preparation method therefor

Methods, systems, and devices for wireless communications are described. In some systems, a device may select antenna elements from a planar array to transmit or receive an orbital angular momentum (OAM) beam. The device may determine a first area (e.g., a first ring area) based on an angular direction over which the device can communicate an OAM beam with a second device and may determine a second area (e.g., a second ring area) on the planar array based on projecting the first area on the planar array. The device may select a set of antenna elements from the planar array that are located within the second area. The device may determine a complex-valued weight for each antenna element of the selected set of antenna elements and may transmit or receive an OAM beam to or from the second device via the set of antenna elements according to the angular direction.

Generating and steering orbital angular momentum beams

Growing community of inventors

Shanghai, China

Jian Li